{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:06:53Z","timestamp":1789103213801,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Other primary malignancies (OPMs) may complicate diagnostic assessment, treatment sequencing, and prognostic evaluation in multiple myeloma (MM). This study characterized the spectrum and timing of OPMs and evaluated their association with overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively screened 461 unique patients with MM treated or followed at a single center between August 8, 2019, and June 6, 2026. Patients with OPMs were categorized as OPM-first, synchronous, or MM-first and matched 1:2 with patients without OPMs by sex, age at MM diagnosis, and year of MM diagnosis. OS was evaluated using Kaplan\u2013Meier analysis, matched-set-stratified log-rank testing, and stratified Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven patients had OPMs, corresponding to a crude proportion of 5.9%. Lung cancer (37.0%) and prostate cancer (18.5%) were the most common OPMs. Ten patients (37.0%) were classified as OPM-first, 12 (44.4%) as synchronous, and 5 (18.5%) as MM-first. OPMs affected MM management in 29.6% of patients, whereas MM or anti-myeloma treatment affected OPM management in 18.5%; treatment was modified because of documented or anticipated overlapping toxicities in 29.6%. Median OS was 46.2 months in cases and was not reached in matched controls. OPMs were associated with inferior OS in the stratified Cox analysis (hazard ratio, 3.92; 95% CI, 1.35\u201311.37;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.012), and the association persisted after MM-first cases were excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lung and prostate cancers were the most common OPMs in this cohort, highlighting the need for heightened clinical attention to these malignancies in patients with MM. The presence of an OPM was associated with inferior OS; however, this finding should be interpreted cautiously because of the small sample size and marked tumor heterogeneity. When both malignancies require active treatment, multidisciplinary assessment is important to determine treatment priority according to disease activity, treatment urgency, and the patient\u2019s overall condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1943171","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:30:35Z","timestamp":1789101035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Changnian","family":"Li","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Wang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Li","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhou","family":"Zang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Lin","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae Insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary Malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary Malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary Malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/s12885-021-08766-9","article-title":"Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study","volume":"21","author":"Tanjak","year":"2021","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516471","article-title":"Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center","volume":"16","author":"Ji","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13581","article-title":"Patterns of previous and secondary Malignancies in patients with multiple myeloma","volume":"106","author":"Langseth","year":"2021","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194919","article-title":"Second primary Malignancy risk in multiple myeloma from 1975 to 2018","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.843","article-title":"Secondary Malignancies in multiple myeloma in Korean patients: a nationwide population-based study","volume":"56","author":"Park","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081940","article-title":"Synchronous\/metachronous multiple primary Malignancies: review of associated risk factors","volume":"12","author":"Pan","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.3.7","article-title":"Managing the patient with multiple primary tumors","volume":"14","author":"Chitwood","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174359","article-title":"Outcome of second primary Malignancies developing in multiple myeloma patients","volume":"15","author":"Avivi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"108","author":"McCurdy","year":"2023","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:30:47Z","timestamp":1789101047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1943171"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1943171","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1943171"}}